You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

EDITORIAL article

Front. Med.

Sec. Gene and Cell Therapy

Gene Editing in Cancer Gene Therapy

  • 1. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 2. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

The final, formatted version of the article will be published soon.

Abstract

Gene editing technologies have rapidly evolved from experimental tools into promising therapeutic strategies in oncology. Advances in programmable nucleases, epigenome-targeting approaches, and delivery systems are reshaping how cancer is studied and treated. This Research Topic, Gene Editing in Cancer Gene Therapy, brings together five complementary contributions- Collectively, these five contributions portray gene editing in cancer therapy as an integrated continuum, from epigenetic regulation and immune modulation to delivery technologies, clinical genomics, and policy frameworks. Rather than focusing on a single technology, this Research Topic highlights the inherently interdisciplinary nature of gene editing and its expanding role in precision oncology.We hope that this Research Topic will serve as a valuable resource for researchers and clinicians seeking to understand the evolving landscape of gene editing in oncology, and that it will stimulate further interdisciplinary efforts bridging molecular engineering, cancer biology, and translational medicine.1.Zhang R, Yao T, Fan M, Jiang X, Wang K, Cui M, Bing K, Xia X. Precision scalpels for the epigenome: next-gen editing tools in targeted therapies. Front Med 2025; 12:1613722.

Summary

Keywords

cancer gene therapy, CAR-T cell therapy, CRISPR-Cas9-based tool, Delivery Systems, gene editing

Received

28 January 2026

Accepted

16 February 2026

Copyright

© 2026 Hou, Zhou, Wang and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xiaotian Xia

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics